{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T01:22:15Z","timestamp":1755998535489},"reference-count":29,"publisher":"Japanese Society of Internal Medicine","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.2169\/internalmedicine.0262-17","type":"journal-article","created":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T18:30:04Z","timestamp":1526581804000},"page":"2895-2900","source":"Crossref","is-referenced-by-count":8,"title":["Life-threatening Hyperkalemia Associated with Axitinib Treatment in Patients with Recurrent Renal Carcinoma"],"prefix":"10.2169","volume":"57","author":[{"given":"Shigeo","family":"Godo","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Japan"},{"name":"Department of Emergency and Critical Care Medicine, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kawamorita","sequence":"additional","affiliation":[{"name":"Department of Urology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Mitsuzuka","sequence":"additional","affiliation":[{"name":"Department of Urology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Kawazoe","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoo","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Tohoku University Hospital, Japan"},{"name":"Division of Emergency and Critical Care Medicine, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Shimokawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Kushimoto","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Tohoku University Hospital, Japan"},{"name":"Division of Emergency and Critical Care Medicine, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs R D 11: 113-126, 2011.","DOI":"10.2165\/11591240-000000000-00000"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Keefe DM, Bateman EH. Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol 9: 98-109, 2011.","DOI":"10.1038\/nrclinonc.2011.192"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Borst DL, Arruda LS, MacLean E, Pithavala YK, Morgado JE. Common questions regarding clinical use of axitinib in advanced renal cell carcinoma. Am J Health Syst Pharm 71: 1092-1096, 2014.","DOI":"10.2146\/ajhp130581"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Matias M, Le Teuff G, Albiges L, et al. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. Eur J Cancer 79: 185-192, 2017.","DOI":"10.1016\/j.ejca.2017.04.015"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Brufau BP, Cerqueda CS, Villalba LB, Izquierdo RS, Gonzalez BM, Molina CN. Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT. Radiographics 33: 1691-1716, 2013.","DOI":"10.1148\/rg.336125110"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol 194: 157-165, 2010.","DOI":"10.2214\/AJR.09.2941"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tsuchiya N, Igarashi R, Suzuki-Honma N, et al. Association of pharmacokinetics of axitinib with treatment outcome and adverse events in advanced renal cell carcinoma patients. J Clin Oncol 33(Suppl): 506, 2015.","DOI":"10.1200\/jco.2015.33.7_suppl.506"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23: 5474-5483, 2005.","DOI":"10.1200\/JCO.2005.04.192"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27: 4462-4468, 2009.","DOI":"10.1200\/JCO.2008.21.7034"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Eto M, Uemura H, Tomita Y, et al. Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma. Cancer Sci 105: 1576-1583, 2014.","DOI":"10.1111\/cas.12546"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tomita Y, Uemura H, Fujimoto H, et al. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. Eur J Cancer 47: 2592-2602, 2011.","DOI":"10.1016\/j.ejca.2011.07.014"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14: 552-562, 2013.","DOI":"10.1016\/S1470-2045(13)70093-7"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378: 1931-1939, 2011.","DOI":"10.1016\/S0140-6736(11)61613-9"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Gumz ML, Rabinowitz L, Wingo CS. An integrated view of potassium homeostasis. N Engl J Med 373: 60-72, 2015.","DOI":"10.1056\/NEJMra1313341"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Lameire NH, Bagga A, Cruz D, et al. Acute kidney injury: an increasing global concern. Lancet 382: 170-179, 2013.","DOI":"10.1016\/S0140-6736(13)60647-9"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hoye A, Clark A. Iatrogenic hyperkalaemia. Lancet 361: 2124, 2003.","DOI":"10.1016\/S0140-6736(03)13724-5"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Gennari FJ. Hypokalemia. N Engl J Med 339: 451-458, 1998.","DOI":"10.1056\/NEJM199808133390707"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 364: 1844-1854, 2011.","DOI":"10.1056\/NEJMra0904569"},{"key":"19","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(07)60903-9","volume":"369","author":"T Nicholaou","year":"2007","unstructured":"19. Nicholaou T, Wong R, Davis ID. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet 369: 1923-1924, 2007.","journal-title":"The Lancet","ISSN":"http:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Joshita S, Yoshizawa K, Sano K, et al. A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome. Intern Med 49: 991-994, 2010.","DOI":"10.2169\/internalmedicine.49.3153"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Witmer AN, Dai J, Weich HA, Vrensen GF, Schlingemann RO. Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J Histochem Cytochem 50: 767-777, 2002.","DOI":"10.1177\/002215540205000603"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290: H560-H576, 2006.","DOI":"10.1152\/ajpheart.00133.2005"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Rodriguez Soriano J. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol 13: 2160-2170, 2002.","DOI":"10.1097\/01.ASN.0000023430.92674.E5"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Karet FE. Mechanisms in hyperkalemic renal tubular acidosis. J Am Soc Nephrol 20: 251-254, 2009.","DOI":"10.1681\/ASN.2008020166"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Leon-Mateos L, Mosquera J, Anton Aparicio L. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors. Redox Biol 6: 421-425, 2015.","DOI":"10.1016\/j.redox.2015.09.007"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34: 2159-2219, 2013.","DOI":"10.1093\/eurheartj\/eht151"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Shimamoto K, Ando K, Fujita T, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 37: 253-390, 2014.","DOI":"10.1038\/hr.2014.20"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Circulation 131: e435-e470, 2015.","DOI":"10.1161\/CIR.0000000000000207"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol 10: 653-662, 2014.","DOI":"10.1038\/nrneph.2014.168"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/19\/57_0262-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T00:38:01Z","timestamp":1538786281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/19\/57_0262-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":29,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0262-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,1]]}}}